research Preparation of finasteride by selective dehydrogenation using IBX
The method produces finasteride with a 92% yield.
Search
for
Sort by
Research
450-480 / 1000+ results
research Adverse effects with finasteride 5 mg/day for patterned hair loss in premenopausal women
Taking 5 mg/day finasteride can cause side effects in women with hair loss, but these are usually mild and fade over time, making the treatment beneficial in the long run.
research マストミス雌雄前立腺における5α-reductase inhibitor (Finasteride)の影響
Finasteride reduces prostate size and DHT in male mastomys but not in females.
research Determination of Oxymatrine in Human Plasma by HPLC-MS
A method was created to measure oxymatrine in human blood.
research Finasteride and male infertility: a case for prospective collaborative research databases?
Finasteride discontinuation increases sperm count in men.
research Improvement of female pattern hair loss with bicalutamide: a time-dependent process
Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
research Stressfulness of Medically Indicated Abortion as Reflected by Hair Concentrations of Stress Hormones Cortisol and Testosterone: A Pilot Study
Hair hormone levels can indicate stress after a medically indicated abortion.
research A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism
All treatments reduce hair growth; low dose flutamide most effective with fewer side effects.
research Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism
Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.
research Expression of Concern: Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome
The article's findings are uncertain and should be viewed with caution.
research The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism
Finasteride effectively reduces hair growth in women with polycystic ovary syndrome or idiopathic hirsutism.
research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
Some gonadal hormone drugs can block filovirus entry into cells.
research Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
research MICROBIAL OXIDATION OF FINASTERIDE WITH MACROPHOMINA PHASEOLINA(KUCC 730)
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen1
MK-386 lowers DHT in blood and skin but not in semen.
research Clinical efficacy and safety of low‐dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism
Low-dose flutamide helps reduce excessive hair growth and is even more effective with birth control, without bad effects on blood fats.
research Pregnancy and neonatal outcome with maternal exposure to finasteride: Case series
Exposure to the hair loss drug finasteride during pregnancy can cause genital anomalies in male babies, but not in female babies. It's best to avoid this drug in women who could potentially become pregnant.
research The curative effect of metformin in combination with dyne-35 on the treatment of polycystic ovary syndrome and on the ovulation rate and pregnancy rate
Metformin combined with dyne-35 increases ovulation and pregnancy rates in PCOS patients.
research DIAGNOSTIC AND THERAPEUTIC UTILITY OF GONADOTROPHIN-RELEASING HORMONE AGONIST IN POSTMENOPAUSAL HYPERANDROGENISM OF OVARIAN ORIGIN
GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.
research Bicalutamide 25 mg associated with minoxidil 1 mg versus minoxidil 1 mg for female-pattern hair loss: A randomized double-blind clinical trial
Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
research A Comparison of the Relative Efficacy of Antiandrogens for the Treatment of Acne in Hyperandrogenic Women
Most antiandrogen treatments effectively reduce acne in hyperandrogenic women, but finasteride is the least effective.
research A Case of the Cons: How Contraception Confused Congenital Adrenal Hyperplasia for Conn
Drospirenone can hide symptoms of certain hormonal disorders, complicating diagnosis.
research Treatment of Hirsutism, Acne and Alopecia with Cyproterone Acetate
Cyproterone acetate was effective in treating acne, hirsutism, and alopecia with few side effects.
research In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors
The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
research Abstract A12: Androgen receptor inhibition is involved in Finasteride-reduced AML cell proliferation
Finasteride reduces AML cell growth by inhibiting androgen receptors.
research Test yolk buffer and antisperm antibodies—interaction?
Finasteride is an effective and well-tolerated treatment for hirsutism.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research 27593 Contraception progestin type and female pattern hair loss
Newer contraceptives with less androgenic progestins may reduce female hair loss.
research Preparation of novel polymeric microspheres for controlled release of finasteride
PPCM microspheres allow controlled finasteride release over 24 hours.